

Human antibodies in the treatment of Ebola

March 01 2016 - The guardian's recent article "Ebola treatment using antibody from survivor's blood passes first trial" describes the therapeutic use of an antibody isolated from Ebola survivor's blood (read more). This example emphasizes the utility of human derived antibodies; one of the goals of *huMemoMAB™* development is to provide a significantly more efficient tool set to the community to more efficiently tackle such diseases in the future.

About Memo Therapeutics AG

Memo Therapeutics is an innovator in the area of recombinant immunoglobulins and human-derived monoclonal antibodies. The technological core of Memo Therapeutics is MemoMAB™ – a technology enabling cost and time-effective molecular cloning and expression of the complete antibody repertoire of one or several human subjects.

Memo Therapeutics capitalizes on the MemoMAB™ platform by developing proprietary technologies and products and by offering services in the area of recombinant immunoglobulins and monoclonal antibodies.